{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:57:48Z","timestamp":1776211068249,"version":"3.50.1"},"reference-count":45,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>T-cell acute lymphoblastic leukemia (T-ALL) and T-cell acute lymphoblastic lymphoma (T-LBL) are aggressive hematological malignancies that are currently treated with high-dose chemotherapy. Over the last several years, the search toward novel and less-toxic therapeutic strategies for T-ALL\/T-LBL patients has largely focused on the identification of cell-intrinsic properties of the tumor cell. However, non\u2013cell-autonomous activation of specific oncogenic pathways might also offer opportunities that could be exploited at the therapeutic level. In line with this, we here show that endogenous interleukin 7 (IL7) can increase the expression of the oncogenic kinase proviral integration site for Moloney-murine leukemia 1 (PIM1) in CD127+ T-ALL\/T-LBL, thereby rendering these tumor cells sensitive to in vivo PIM inhibition. In addition, using different CD127+ T-ALL\/T-LBL xenograft models, we also reveal that residual tumor cells, which remain present after short-term in vivo chemotherapy, display consistent upregulation of PIM1 as compared with bulk nontreated tumor cells. Notably, this effect was transient as increased PIM1 levels were not observed in reestablished disease after abrogation of the initial chemotherapy. Furthermore, we uncover that this phenomenon is, at least in part, mediated by the ability of glucocorticoids to cause transcriptional upregulation of IL7RA in T-ALL\/T-LBL patient-derived xenograft (PDX) cells, ultimately resulting in non\u2013cell-autonomous PIM1 upregulation by endogenous IL7. Finally, we confirm in vivo that chemotherapy in combination with a pan-PIM inhibitor can improve leukemia survival in a PDX model of CD127+ T-ALL. Altogether, our work reveals that IL7 and glucocorticoids coordinately drive aberrant activation of PIM1 and suggests that IL7-responsive CD127+ T-ALL and T-LBL patients could benefit from PIM inhibition during induction chemotherapy.<\/jats:p>","DOI":"10.1182\/blood.2019003880","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T19:13:02Z","timestamp":1581621182000},"page":"1685-1695","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma"],"prefix":"10.1182","volume":"135","author":[{"given":"Renate","family":"De Smedt","sequence":"first","affiliation":[{"name":"Department of Biomolecular Medicine, Ghent University, Ghent, Belgium;"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium;"}]},{"given":"Julie","family":"Morscio","sequence":"first","affiliation":[{"name":"Department of Biomolecular Medicine, Ghent University, Ghent, Belgium;"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium;"}]},{"given":"Lindy","family":"Reunes","sequence":"first","affiliation":[{"name":"Department of Biomolecular Medicine, Ghent University, Ghent, Belgium;"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7230-3690","authenticated-orcid":false,"given":"Juliette","family":"Roels","sequence":"first","affiliation":[{"name":"Department of Biomolecular Medicine, Ghent University, Ghent, Belgium;"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium;"},{"name":"Department of Diagnostic Sciences, Ghent University, Ghent, Belgium;"}]},{"given":"Valentina","family":"Bardelli","sequence":"first","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Center for Hemato-Oncology Research (CREO), University of Perugia, Perugia, Italy;"}]},{"given":"Beatrice","family":"Lintermans","sequence":"first","affiliation":[{"name":"Department of Biomolecular Medicine, Ghent University, Ghent, Belgium;"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium;"}]},{"given":"Wouter","family":"Van Loocke","sequence":"first","affiliation":[{"name":"Department of Biomolecular Medicine, Ghent University, Ghent, Belgium;"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium;"}]},{"given":"Afonso","family":"Almeida","sequence":"first","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal;"}]},{"given":"Laurence C.","family":"Cheung","sequence":"first","affiliation":[{"name":"Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia;"},{"name":"School of Pharmacy and Biomedical Sciences, Curtin University, Perth, WA, Australia;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1836-4075","authenticated-orcid":false,"given":"Rishi S.","family":"Kotecha","sequence":"first","affiliation":[{"name":"Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia;"},{"name":"School of Pharmacy and Biomedical Sciences, Curtin University, Perth, WA, Australia;"}]},{"given":"Marc R.","family":"Mansour","sequence":"first","affiliation":[{"name":"Department of Haematology, University College London Cancer Institute, London, United Kingdom;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5644-424X","authenticated-orcid":false,"given":"Anne","family":"Uyttebroeck","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology-Oncology, University Hospitals Leuven, Leuven, Belgium;"},{"name":"Department of Oncology, Katholieke Universiteit (KU) Leuven, Leuven, Belgium;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4719-1935","authenticated-orcid":false,"given":"Peter","family":"Vandenberghe","sequence":"first","affiliation":[{"name":"Department of Hematology, University Hospitals Leuven, Leuven, Belgium;"},{"name":"Center for Human Genetics, KU Leuven, Leuven, Belgium;"}]},{"given":"Roberta","family":"La Starza","sequence":"first","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Center for Hemato-Oncology Research (CREO), University of Perugia, Perugia, Italy;"}]},{"given":"Cristina","family":"Mecucci","sequence":"first","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Center for Hemato-Oncology Research (CREO), University of Perugia, Perugia, Italy;"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8733-4027","authenticated-orcid":false,"given":"Tim","family":"Lammens","sequence":"first","affiliation":[{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium;"},{"name":"Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium; and"}]},{"given":"Nadine","family":"Van Roy","sequence":"first","affiliation":[{"name":"Department of Biomolecular Medicine, Ghent University, Ghent, Belgium;"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium;"}]},{"given":"Barbara","family":"De Moerloose","sequence":"first","affiliation":[{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium;"},{"name":"Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium; and"}]},{"given":"Jo\u00e3o T.","family":"Barata","sequence":"first","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal;"}]},{"given":"Tom","family":"Taghon","sequence":"first","affiliation":[{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium;"},{"name":"Department of Diagnostic Sciences, Ghent University, Ghent, Belgium;"}]},{"given":"Steven","family":"Goossens","sequence":"first","affiliation":[{"name":"Department of Biomolecular Medicine, Ghent University, Ghent, Belgium;"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium;"},{"name":"Molecular and Cellular Oncology Laboratory, Department for Biomedical Molecular Biology, Ghent University, Ghent, Belgium"}]},{"given":"Pieter","family":"Van Vlierberghe","sequence":"first","affiliation":[{"name":"Department of Biomolecular Medicine, Ghent University, Ghent, Belgium;"},{"name":"Cancer Research Institute Ghent (CRIG), Ghent, Belgium;"}]}],"member":"234","reference":[{"issue":"2","key":"2020050711242246800_B1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2141.2008.07314.x","article-title":"Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia","volume":"143","author":"Van Vlierberghe","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"2020050711242246800_B2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood-2009-07-233445","article-title":"A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia\/lymphoma","volume":"115","author":"Lin","year":"2010","journal-title":"Blood"},{"issue":"18","key":"2020050711242246800_B3","doi-asserted-by":"crossref","first-page":"30199","DOI":"10.18632\/oncotarget.16320","article-title":"Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset","volume":"8","author":"Padi","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"2020050711242246800_B4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2159-8290.CD-17-0583","article-title":"HOXA9 cooperates with activated JAK\/STAT signaling to drive leukemia development","volume":"8","author":"de Bock","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"2020050711242246800_B5","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/s41375-018-0031-2","article-title":"High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK\/STAT activation or t(6;7)(p21;q34)\/TRB@-PIM1 rearrangement","volume":"32","author":"La Starza","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2020050711242246800_B6","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.3324\/haematol.2018.199257","article-title":"Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma","volume":"104","author":"De Smedt","year":"2019","journal-title":"Haematologica"},{"issue":"17","key":"2020050711242246800_B7","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/bloodadvances.2018021063","article-title":"STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells","volume":"2","author":"Ribeiro","year":"2018","journal-title":"Blood Adv"},{"issue":"11","key":"2020050711242246800_B8","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","article-title":"Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2020050711242246800_B9","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/leu.2017.136","article-title":"JAK\/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias","volume":"31","author":"Delgado-Martin","year":"2017","journal-title":"Leukemia"},{"issue":"16","key":"2020050711242246800_B10","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"issue":"9617","key":"2020050711242246800_B11","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"2020050711242246800_B12","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2020050711242246800_B13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjh.15983","article-title":"Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL)","volume":"186","author":"Hofmans","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"2020050711242246800_B14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.immuni.2018.01.004","article-title":"Glucocorticoids drive diurnal oscillations in T cell distribution and responses by inducing interleukin-7 receptor and CXCR4","volume":"48","author":"Shimba","year":"2018","journal-title":"Immunity"},{"issue":"12","key":"2020050711242246800_B15","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.4049\/jimmunol.174.12.7800","article-title":"Transcriptional regulation of the mouse IL-7 receptor alpha promoter by glucocorticoid receptor","volume":"174","author":"Lee","year":"2005","journal-title":"J Immunol"},{"issue":"5","key":"2020050711242246800_B16","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4049\/jimmunol.168.5.2212","article-title":"Positive effects of glucocorticoids on T cell function by up-regulation of IL-7 receptor alpha","volume":"168","author":"Franchimont","year":"2002","journal-title":"J Immunol"},{"issue":"1","key":"2020050711242246800_B17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00251-016-0948-4","article-title":"Transcriptional regulation of the IL-7R\u03b1 gene by dexamethasone and IL-7 in primary human CD8 T cells","volume":"69","author":"Kakal","year":"2017","journal-title":"Immunogenetics"},{"issue":"1","key":"2020050711242246800_B18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/1078-0432.CCR-16-0230","article-title":"The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care","volume":"23","author":"Pa\u00edno","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2020050711242246800_B19","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/nm.4198","article-title":"PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer [published corrections appear in Nat Med. 2017;23(4):526 and Nat Med. 2017;23(6):788]","volume":"22","author":"Bras\u00f3-Maristany","year":"2016","journal-title":"Nat Med"},{"issue":"2","key":"2020050711242246800_B20","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju407","article-title":"PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer","volume":"107","author":"Kirschner","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2020050711242246800_B21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jbior.2018.09.012","article-title":"IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: an update","volume":"71","author":"Oliveira","year":"2019","journal-title":"Adv Biol Regul"},{"issue":"12","key":"2020050711242246800_B22","doi-asserted-by":"crossref","first-page":"e9443","DOI":"10.15252\/emmm.201809443","article-title":"PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia","volume":"10","author":"Richter-Pecha\u0144ska","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"21","key":"2020050711242246800_B23","doi-asserted-by":"crossref","first-page":"8373","DOI":"10.1021\/acs.jmedchem.5b01275","article-title":"Identification of N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a potent and selective proviral insertion site of Moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitor in clinical trials for hematological malignancies","volume":"58","author":"Burger","year":"2015","journal-title":"J Med Chem"},{"issue":"12","key":"2020050711242246800_B24","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1038\/s41375-019-0482-0","article-title":"The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and\/or refractory multiple myeloma","volume":"33","author":"Raab","year":"2019","journal-title":"Leukemia"},{"issue":"21","key":"2020050711242246800_B25","doi-asserted-by":"crossref","first-page":"E5410","DOI":"10.3390\/ijms20215410","article-title":"Insights into the interaction mechanisms of the proviral integration site of Moloney murine leukemia virus (Pim) kinases with Pan-Pim inhibitors PIM447 and AZD1208: a Molecular Dynamics Simulation and MM\/GBSA Calculation Study","volume":"20","author":"Chen","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2020050711242246800_B26","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","article-title":"Glucocorticoid use in acute lymphoblastic leukaemia","volume":"11","author":"Inaba","year":"2010","journal-title":"Lancet Oncol"},{"issue":"19","key":"2020050711242246800_B27","doi-asserted-by":"crossref","first-page":"14194","DOI":"10.1074\/jbc.M700377200","article-title":"Regulation of the interleukin-7 receptor alpha promoter by the Ets transcription factors PU.1 and GA-binding protein in developing B cells","volume":"282","author":"DeKoter","year":"2007","journal-title":"J Biol Chem"},{"issue":"1","key":"2020050711242246800_B28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0092-8674(84)90309-X","article-title":"Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region","volume":"37","author":"Cuypers","year":"1984","journal-title":"Cell"},{"issue":"1","key":"2020050711242246800_B29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2986","article-title":"For better or for worse: the role of Pim oncogenes in tumorigenesis","volume":"11","author":"Nawijn","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2020050711242246800_B30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/med.21284","article-title":"The PIM family of serine\/threonine kinases in cancer","volume":"34","author":"Narlik-Grassow","year":"2014","journal-title":"Med Res Rev"},{"key":"2020050711242246800_B31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-014-0095-z","article-title":"Pim kinases in hematological malignancies: where are we now and where are we going?","volume":"7","author":"Mondello","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2020050711242246800_B32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-4889(02)00347-6","article-title":"Phosphorylation of the cell cycle inhibitor p21Cip1\/WAF1 by Pim-1 kinase","volume":"1593","author":"Wang","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"2020050711242246800_B33","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/0008-5472.CAN-08-0634","article-title":"Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels","volume":"68","author":"Morishita","year":"2008","journal-title":"Cancer Res"},{"issue":"35","key":"2020050711242246800_B34","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/onc.2008.123","article-title":"Pim kinase-dependent inhibition of c-Myc degradation","volume":"27","author":"Zhang","year":"2008","journal-title":"Oncogene"},{"issue":"1-3","key":"2020050711242246800_B35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.febslet.2004.06.050","article-title":"Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site","volume":"571","author":"Aho","year":"2004","journal-title":"FEBS Lett"},{"issue":"2","key":"2020050711242246800_B36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/mol.109.061713","article-title":"Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression","volume":"78","author":"Xie","year":"2010","journal-title":"Mol Pharmacol"},{"issue":"9","key":"2020050711242246800_B37","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4161\/cbt.8.9.8210","article-title":"PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells","volume":"8","author":"Zhang","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"2020050711242246800_B38","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1084\/jem.20082074","article-title":"Dissection of PIM serine\/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration","volume":"206","author":"Grundler","year":"2009","journal-title":"J Exp Med"},{"issue":"13","key":"2020050711242246800_B39","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1128\/MCB.24.13.6104-6115.2004","article-title":"Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors","volume":"24","author":"Mikkers","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"20","key":"2020050711242246800_B40","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1093\/nar\/21.20.4750","article-title":"In vivo analysis of Pim-1 deficiency","volume":"21","author":"Laird","year":"1993","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"2020050711242246800_B41","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"issue":"10","key":"2020050711242246800_B42","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/leu.2016.100","article-title":"Loss-of-function mutations of Dynamin 2 promote T-ALL by enhancing IL-7 signalling","volume":"30","author":"Tremblay","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"2020050711242246800_B43","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood-2018-09-872945","article-title":"Oncogenic basic amino acid insertions at the extracellular juxtamembrane region of IL7RA cause receptor hypersensitivity","volume":"133","author":"Weijenborg Campos","year":"2019","journal-title":"Blood"},{"issue":"48","key":"2020050711242246800_B44","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1038\/s41388-019-0921-4","article-title":"T-cell acute lymphoblastic leukemia displays autocrine production of interleukin-7","volume":"38","author":"Buffi\u00e8re","year":"2019","journal-title":"Oncogene"},{"issue":"11","key":"2020050711242246800_B45","doi-asserted-by":"crossref","first-page":"7325","DOI":"10.4049\/jimmunol.175.11.7325","article-title":"Murine and human IL-7 activate STAT5 and induce proliferation of normal human pro-B cells","volume":"175","author":"Johnson","year":"2005","journal-title":"J Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/19\/1685\/1726918\/bloodbld2019003880.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/19\/1685\/1726918\/bloodbld2019003880.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T15:25:01Z","timestamp":1588865101000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/19\/1685\/452489\/Targeting-cytokine-and-therapyinduced-PIM1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":45,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,5,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003880","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]}}}